Larvol Delta - Camrelizumab-Combined-With-Rivoceranib-and-Hepatic-Arterial-Infusion-Chemotherapy-HAIC-as-Conversion-Therapy-for-Potentially-Resectable-Hepatocellular-CarcinomaHCC

AiTan (rivoceranib) - Elevar Therapeutics

AiRuiKa (camrelizumab) - Elevar Therapeutics

http://clinicaltrials.gov/ct2/show/NCT06796803

Jul 18, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next